HAE - Haemonetics Company Company Value to Earnings Growth Ratio

Haemonetics Corporation relies on stable demand in the plasma collection sector, which establishes it as a defensive asset. Growth is supported by the acquisition of innovative vascular surgery startups. The growth stock attractiveness indicator clearly demonstrates the current valuation, where the value of 1.44 reflects this status. However, investments are limited by strict FDA oversight and a dependence on the availability of specific consumables.

The PEG ratio assesses the fairness of the market price by correlating the P/E ratio with expected earnings growth, where values below one signal that an asset is undervalued relative to its expansion. By analyzing the relationship between P/E and growth rates, an investor can determine the efficiency of the Haemonetics Corporation business model, where high margins on the final assembly of medical systems combined with moderate component outsourcing provide sustainable capitalization potential.